Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies

We studied 74 patients with progressive, asymmetrical lower motor neuron syndromes. Clinical features of these patients, including age, sex, disease duration, patterns of weakness, and reflex changes, were evaluated by review of records. In each patient the clinical features were compared to the type of nerve conduction abnormalities and to the specificities of high‐titer serum antiglycolipid antibodies. Antibody specificities were determined by an enzyme‐linked immunosorbent assay using purified glycolipids and carbohydrates as substrates. Our results show that high titers of antibodies to glycolipids are common in sera of patients with lower motor neuron syndromes. Selective patterns of reactivity indicate that specific carbohydrate epitopes on the glycolipids are the targets of the high‐titer antibodies in individual patients with lower motor neuron syndromes. Several distinct lower motor neuron syndromes can be identified based on clinical, physiological, and antiglycolipid antibody characteristics. These syndromes include multifocal motor neuropathy with evidence of multifocal conduction block on motor, but not sensory, axons and frequent (84 ) high titers of anti‐GM1 ganglioside antibodies; a lower motor neuron syndrome with predominantly distal weakness early in the disease course, no conduction block, and a high incidence (64%) of anti‐GM1 antibodies; and a lower motor neuron syndrome with predominant early weakness in proximal muscles and serum antibodies to asialo GM1 that do not cross‐react with GM1 ganglioside.

[1]  A. Pestronk,et al.  Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy , 1989, Journal of Neuroimmunology.

[2]  R. Knobler,et al.  Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia , 1989, Annals of neurology.

[3]  S. Kusunoki,et al.  Motor dominant neuropathy and IgM paraproteinemia: the IgM M-protein binds to specific gangliosides , 1989, Journal of Neuroimmunology.

[4]  J. Kelly,et al.  Motor neuropathy with multifocal conduction blocks , 1989, Muscle & nerve.

[5]  A. Pestronk,et al.  Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis , 1989, Annals of neurology.

[6]  M. Carreras,et al.  Motor neuron disease in the province of Ferrara, Italy, in 1964–1982 , 1988, Neurology.

[7]  N. Latov,et al.  Monoclonal IgM in two patients with motor neuron disease bind to the carbohydrate antigens Gal(β1–3)GalNAc and Gal(β1–3)GlcNAc , 1988, Journal of Neuroimmunology.

[8]  A. Pestronk,et al.  Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis , 1988, Neurology.

[9]  A. Pestronk,et al.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside , 1988, Annals of neurology.

[10]  E. Kabat,et al.  Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto‐N ‐tetraose associated with human motor neuron disease , 1988, Neurology.

[11]  A. Steck,et al.  Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b , 1988, Annals of neurology.

[12]  D. Mikol,et al.  A phosphatidylinositol-linked peanut agglutinin-binding glycoprotein in central nervous system myelin and on oligodendrocytes , 1988, The Journal of cell biology.

[13]  G. Parry,et al.  Multifocal acquired demyelinating neuropathy masqurading as motor neuron disease , 1988, Muscle & nerve.

[14]  E. Lisowska Antigenic properties of human erythrocyte glycophorins. , 1988, Advances in experimental medicine and biology.

[15]  J. Mcleod,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. , 1987, Brain : a journal of neurology.

[16]  M. Rapport,et al.  Preparation and Specificity of 11 Monoclonal Antibodies to GM1 Ganglioside , 1986, Journal of neurochemistry.

[17]  A. Hays,et al.  Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease , 1986, Neurology.

[18]  W F Brown,et al.  The pathological basis of conduction block in human neuropathies. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[19]  J U Baenziger,et al.  The role of glycosylation in protein recognition. Warner-Lambert Parke-Davis Award lecture. , 1985, The American journal of pathology.

[20]  D. Marcus,et al.  Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. , 1984, Journal of immunology.

[21]  M. Rapport,et al.  Present status of the immunology of gangliosides. , 1984, Advances in experimental medicine and biology.

[22]  D. Pleasure,et al.  Peripheral Nervous System Myelin and Schwann Cell Glycoproteins: Identification by Lectin Binding and Partial Purification of a Peripheral Nervous System Myelin‐Specific 170,000 Molecular Weight Glycoprotein , 1983, Journal of neurochemistry.

[23]  N. Murray,et al.  Chronic asymmetrical spinal muscular atrophy , 1983, Journal of the Neurological Sciences.

[24]  G. Springer,et al.  Origin of Anti‐Thomsen‐Friedenreich (T) and Tn Agglutinins in Man and in White Leghorn Chicks , 1981, British journal of haematology.

[25]  I. Sobue,et al.  Juvenile type of distal and segmental muscular atrophy of upper extremities , 1978, Annals of neurology.

[26]  P. Dyck,et al.  Chronic inflammatory polyradiculoneuropathy. , 1975, Mayo Clinic proceedings.

[27]  M. Naiki,et al.  Properties of antisera to ganglioside GM1 and asialo GM1. , 1974, Journal of immunology.

[28]  C. Marsden,et al.  Chronic spinal muscular atrophy in adults. 2. Other forms. , 1969, Journal of the neurological sciences.

[29]  G. Springer,et al.  INACTIVATION OF HUMAN ERYTHROCYTE AGGLUTINOGENS M AND N BY INFLUENZA VIRUSES AND RECEPTOR-DESTROYING ENZYME. , 1958, Proceedings of the National Academy of Sciences of the United States of America.